Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry

BACKGROUND: Despite standard-of-care androgen-deprivation therapy and an increasing number of treatment options, the mortality rate for prostate cancer remains high. Progress to metastatic castration-resistant prostate cancer (mCRPC) necessitates additional treatments. Abiraterone acetate plus predn...

Descripción completa

Detalles Bibliográficos
Autores principales: Bjartell, Anders, Lumen, Nicolaas, Maroto, Pablo, Paiss, Thomas, Gomez-Veiga, Francisco, Birtle, Alison, Kramer, Gero, Kalinka, Ewa, Spaëth, Dominique, Feyerabend, Susan, Matveev, Vsevolod, Lefresne, Florence, Lukac, Martin, Wapenaar, Robert, Costa, Luis, Chowdhury, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105236/
https://www.ncbi.nlm.nih.gov/pubmed/33826036
http://dx.doi.org/10.1007/s11523-021-00807-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105236/
https://www.ncbi.nlm.nih.gov/pubmed/33826036
http://dx.doi.org/10.1007/s11523-021-00807-4

Ejemplares similares